Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with NgFUS for Relapsed and Progressive Diffuse Midline Glioma and Other High Grade Brain Tumors
NCT07664176Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in diffuse midline glioma (DMG) and brain tumor (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Percentage of patients completing at least two cycles of planned therapy at 8 weeks. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
diffuse midline glioma (DMG)brain tumor
Beyond the preview
Go deeper on NCT07664176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664176.